Results of the double-blind phase 3 CELESTIAL study, presented at the 2018 Gastrointestinal Cancers Symposium, demonstrated efficacy of cabozantinib in patients with HCC who were previously treated with sorafenib.
Recent studies have suggested that married patients experience a survival benefit for various cancers; marriage has been associated with earlier detection, undergoing treatment, as well as better economic status and social support.
Optimal Therapy for Patients with Hepatocellular Carcinoma and Resistance or Intolerance to Sorafenib: Challenges and SolutionsDecember 08, 2017
[Journal of Hepatocellular Carcinoma] This research examines systemic therapies that can be considered in patients with sorafenib refractory hepatocellular carcinoma.
Study presented at the AASLD The Liver Meeting 2017 demonstrated the effect of regular aspirin use on risk of hepatocellular carcinoma in patients with chronic HBV.
Reducing the initial dose of sorafenib was shown to have some benefits — such as reduced pill burden, lower costs, and decreased AE-related discontinuation rates — and OS was noninferior compared with the standard dose in patients with hepatocellular carcinoma.
New data presented at the International Liver Congress 2017 suggest that nivolumab may produce long-term benefits in sorafenib-experienced patients with advanced HCC.
[Journal of Hepatocellular Carcinoma] This research examines the outcomes of HCC patients with BDTT in a single institution.
Treatment with cabozantinib was active and associated with manageable toxicities in patients with hepatocellular carcinoma.
[Journal of Hepatocellular Carcinoma] This research examines the medical challenges presented by pediatric hepatocellular carcinoma (HCC).
Researchers have found that hepatitis C virus infection is associated with an elevated risk for developing bile duct cancers and diffuse large B-cell lymphoma.
Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: The Evidence to DateDecember 08, 2016
[Journal of Hepatocellular Carcinoma] This research examines tivantinib and its therapeutic profile in the management of hepatocellular carcinoma.
[Journal of Hepatocellular Carcinoma] This research examines the screening modalities, diagnosis, staging, and treatment of hepatocellular carcinoma (HCC), the most common primary liver malignancy.
Role of Regorafenib as Second-line Therapy and Landscape of Investigational Treatment Options in Advanced Hepatocellular CarcinomaOctober 27, 2016
[Journal of Hepatocellular Carcinoma] This review examines the multikinase inhibitors sorafenib and regorafenib, inhibitors of the MET pathway, and immunotherapeutics for the treatment of advanced hepatocellular carcinoma.
In patients with advanced HCC and a baseline αFP level of 400 ng/mL or more, a survival benefit with second-line ramucirumab therapy was observed for those with Child-Pugh scores of 5 and 6.
The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.
In patients with advanced hepatocellular carcinoma (HCC), adding doxorubicin to sorafenib did not improve overall survival or progression-free survival and resulted in higher toxicity compared to sorafenib alone, results from a phase 3 study presented at the ASCO 2016 Annual Meeting have shown.
Metabolic disorders contribute more to the incidence of hepatocellular carcinoma (HCC) incidence than any other risk factor.
The addition of mapatumumab to sorafenib did not improve time to progression, progression-free survival, overall survival, or objective response.
Long-term therapy with tenofovir was associated with a decreased incidence of HCC among patients with chronic HBV infection without cirrhosis.
Significant clinical variations have been identified among patients with hepatocellular carcinoma (HCC).
[Journal of Hepatocellular Carcinoma] This article explores the involvement of the TLR pathway in the initiation, progression, and metastasis of hepatocellular carcinoma (HCC).
Diet and nutrition are significant factors in preventing hepatic diseases progressing to hepatocellular carcinoma, and coffee is high on the list of good foods.
By combining a zebrafish model of liver cancer with data from human tumors, researchers hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma.
Highest risk seen for Latinos; estimated 26 percent of HCC cases in Latinos due to diabetes
Few patients with HCC are candidates for curative treatment at diagnosis. However, a new study demonstrated that stereotactic body radiotherapy...
Treating hepatocellular carcinoma with transarterial chemoembolization and selective internal radiotherapyMay 09, 2013
New light was shed on the use of TACE and SIRT in the treatment of hepatocellular carcinoma (HCC) by data from clinical trials presented at the International Liver Congress 2013 in Amsterdam, the Netherlands.
New data from two clinical trials presented at the International Liver Congress 2013 demonstrated substantial improvements in the detection of both HCC and cholangiocarcinoma using diagnostic urine tests.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|